Spaulding Clinical Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$10,535	1
2023	Research	$62,709	3
2022	Research	$573	1
2021	Research	$2,204,942	25
2020	Research	$2,719,317	60
2019	Research	$327,482	14

Breakdown

Who paid Research payments · program years 2019–2024

Allergan Inc. $2,193,885 70 payments
AbbVie, Inc. $1,887,033 20 payments
BioCryst Pharmaceuticals, Inc. $1,063,657 7 payments
Xeris Pharmaceuticals, Inc. $103,919 1 payment
Novartis Pharmaceuticals Corporation $73,244 4 payments
Merck Sharp & Dohme Corporation $3,820 2 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects $1,657,120 14 payments
A Phase 1, Randomized, double-bline, placebo-controlled dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of sing and multiple doses of BCX9250 in healthy subjects $852,914 4 payments
Phase 1 Ddi Gemfibrizol $514,105 14 payments
An Open-Label, Multiple-Dose, Parallel Cohort, Drug-Drug Interaction Study Between Atogepant and Topiramate in Healthy Participants $479,985 8 payments
Food Effect Evaluation of Immediate Release Formulation of Atogepant $448,494 16 payments
ATH - API PK comparability study $351,137 6 payments
Phase 1b, 2-part, multi-center, open-label, fixed-sequence drug-drug interaction study in 40 male and female participants who have been diagnosed with migraine for at least 1 year and are aged 18 through 50 years. $292,707 17 payments
A Phase 1 Randomized double-bline placebo-controlled dose-ranging study to evaluate the safety tolerability and pharmacokinetics of sing and multiple doses of BCX9250 in healthy subjects $210,744 3 payments
A Phase 1b, Open-label, Fixed-sequence, Safety, Tolerability and Drug-drug Interaction Study Between Atogepant and Ubrogepant in Participants with a History of Migraine $117,355 4 payments
A Phase 1b, Open-label, Fixed-sequence, Safety, Tolerability and Drug-drug Interaction Study Between Atogepant and Ubrogepant in Participants with a History of Migraine $112,558 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.